Maria Romano
Montefiore Medical Center
8 Papers
30 Citations
Maria Romano is an academic researcher from Montefiore Medical Center. The author has contributed to research in topics: Cancer & Insulin. The author has an hindex of 5, co-authored 8 publications.
Chat about Author
Papers
Targeting insulin inhibition as a metabolic therapy in advanced cancer: A pilot safety and feasibility dietary trial in 10 patients
Eugene J. Fine,C J Segal-Isaacson,Richard D. Feinman,Silvia Herszkopf,Maria Romano,Norica Tomuta,Amanda Bontempo,Abdissa Negassa,Joseph A. Sparano +8 more
TL;DR: Preliminary data demonstrate that an insulin-inhibiting diet is safe and feasible in selected patients with advanced cancer, and the extent of ketosis, but not calorie deficit or weight loss, correlated with stable disease or partial remission.
198
Current Recommendations and Novel Strategies for the Management of Skin Toxicities Related to Anti-EGFR Therapies in Patients with Metastatic Colorectal Cancer.
Maria Carmela Annunziata,Alfonso De Stefano,Gabriella Fabbrocini,Silvana Leo,Paolo Marchetti,Maria Romano,Ivana Romano +6 more
TL;DR: A treatment approach for papulopustular rash based on the combination of fusidic acid plus betamethasone in a lipid-enriched topical formulation and the effectiveness of this approach is documented by the presentation of five cases successfully treated in clinical practice for anti-EGFR therapy-related rash.
20
Prophylactic Dermatologic Treatment of Afatinib-Induced Skin Toxicities in Patients with Metastatic Lung Cancer: A Pilot Study.
Maria Pia Fuggetta,Maria Rita Migliorino,Serena Ricciardi,Giorgia Amira Osman,Daniela Iacono,Alvaro Leone,Alessandra Lombardi,Giampietro Ravagnan,Stefania Greco,Daniele Remotti,Maria Romano +10 more
- 31 Jan 2019
TL;DR: It was shown that a PD-based cream can reduce the incidence of grade ≥2 skin toxicities in patients treated with afatinib, and this study evaluated the effect of topical application of a moisturizer containing PD to prevent skin rash in patients with mutated non-small cell lung cancer treated withAfatinib.
A pilot safety and feasibility trial of a reduced carbohydrate diet in patients with advanced cancer.
E. J. Fine,C. J. Segal-Isaacson,R. D. Feinman,S. Herszkopf,Maria Romano,N. Tomuta,Amanda Bontempo,Joseph A. Sparano +7 more
TL;DR: A carbohydrate restricted diet is feasible in selected patients with advanced cancer, resulting in reduced serum insulin concentration and ketosis, supporting further evaluation of CR as a means of insulin secretory inhibition, and as a complementary approach in conjunction with standard and endocrine therapies.
8
•Journal Article
A pilot safety and feasibility trial of a reduced carbohydrate diet in patients with advanced cancer
Eugene J. Fine,C J Segal-Isaacson,Silvia Herzkopf,Joseph A. Sparano,Maria Romano,Richard D. Feinman,Nora Tomuta,Amanda Bontempo +7 more
TL;DR: In this article, the authors examined the feasibility of carbohydrate restricted diets in patients with advanced FDG-avid cancers and compared exit vs. baseline PET scan changes as surrogate measures for tumor response.
7